Loading...
NPI 1891280541 · Tulsa, OK · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Wellness Health Group, LLC is a clinical medical laboratory provider located in Tulsa, Oklahoma. This profile covers 84 Medicare and 62 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Wellness Health Group, LLC |
| Address | 7780 E 106th St Ste 205 |
| City | Tulsa |
| State | OK |
| ZIP | 74133 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | June 26, 2018 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $5.2M |
| Medicaid | $727K |
WELLNESS HEALTH GROUP, LLC operates as a Clinical Medical Laboratory with a clear molecular infectious-disease testing orientation: its Medicare portfolio is dominated by nucleic acid amplification and multiplex infectious-agent panels such as 87150, 87801, and 87637, and its Medicaid mix is similarly focused on high-volume SARS–CoV–2 and multiplex testing codes including U0003 and 87801. The presence of many amplified probe and multiplex codes indicates the lab’s operational focus is on high-throughput molecular diagnostics rather than primary-care point testing.
Revenue concentration is high across both payers: the provider’s top 3 Medicare codes account for 64.3% of Medicare revenue (driven by 87150, 87801, 87637), and the top 3 Medicaid codes account for 68.3% of Medicaid revenue (driven by U0003, 87801, 87637). These shares show that a few molecular assays are the primary revenue drivers rather than a broad spread of routine chemistry or hematology panels.
On Medicare, WELLNESS HEALTH GROUP is a national high-volume performer for several key molecular assays: 87801 ranks #9 of 561 providers nationally (99th percentile; extreme outlier, far above typical national volume for this code), 87150 ranks #8 of 190 providers nationally (96th percentile; notably above typical national volume for this code), and 87637 ranks #22 of 1141 providers nationally (98th percentile; typical, unremarkable volume for this code). Taken together, these ranks indicate the provider is a major national participant in select amplified-nucleic-acid testing niches rather than a generalist lab.
In the Oklahoma Medicaid market the competitive picture is more mixed but shows strong state-level positions for select assays: 87801 ranks #2 of 18 providers in-state (94th percentile; typical, unremarkable volume for this code) and 87500 ranks #1 of 12 providers in-state (100th percentile; notably above typical state volume for this code). By contrast, U0003 — which represents 39.7% of this provider’s Medicaid revenue — ranks #10 of 52 providers in-state (82th percentile; typical, unremarkable volume for this code), suggesting leadership in some targeted tests but only mid-to-high positioning for high-throughput SARS–CoV–2 claims in-state.
The provider’s payer mix is Medicare-dominant: lifetime Medicare revenue is $5.2M compared with $727K in Medicaid, so Medicare is the primary source of scale for this operation while Medicaid represents a smaller, secondary revenue stream. This asymmetry implies strategic dependence on Medicare-testing volumes for overall financial scale.
Operational signals point to a broad specimen-collection footprint and outreach capability: P9603 shows 34.5K claims and $34.5K revenue on Medicare (rank #113 of 267 providers nationally, 58th percentile; typical, unremarkable volume for this code), and 36415 has 6.2K claims and $24.7K revenue on Medicare. The combination of travel-allowance claims and large phlebotomy counts is consistent with frequent home- or facility-based specimen collection as part of the lab’s service model.
Despite molecular tests dominating revenue, the practice also bills routine clinical panels at lower share — codes like 80053 ($38K on Medicare), 80061 ($22.9K on Medicare; $7.1K on Medicaid), and 85025 ($29.8K on Medicare; $6.7K on Medicaid) appear across both payers but contribute only small percentages of total revenue. This mix indicates the lab maintains standard chemistry and hematology capabilities but concentrates commercial and operational effort on higher-margin, higher-volume molecular assays.
The provider’s NPI was enumerated 2018-06-26 (~8 years ago), indicating a relatively recent market entrant that has nonetheless achieved high volumes for specialized molecular testing in a short period. That tenure, coupled with extreme outlier status on codes like 87801, suggests rapid build-out of targeted molecular services rather than decades-long, diversified legacy laboratory operations.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
84 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 55,970 | $30 | $1.9M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 13,990 | $70 | $965K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 2,010 | $140 | $281.4K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 4,720 | $30 | $160.5K |
| 87651 | The lab analyst performs a test for the bacteria Streptococcus, group A, using amplified nucleic acid probe technique. Strep A commonly causes acute pharyngitis, or strep throat. | 4,670 | $30 | $158.6K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 4,670 | $30 | $158.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 4,660 | $30 | $158.5K |
| 87581 | The lab analyst performs a test for Mycoplasma pneumonia, a bacteria, using amplified nucleic acid probe technique. | 4,480 | $30 | $152.4K |
| 87541 | The lab analyst performs a test for the bacteria Legionella pneumophila using amplified nucleic acid probe technique. L. pneumophila can inhabit facility water and air conditioning systems and may… | 4,470 | $30 | $152K |
| 87486 | The lab analyst performs a test for Chlamydia pneumoniae using amplified nucleic acid probe technique. Chlamydia pneumoniae also known as TWAR, Taiwan Acute Respiratory agent, commonly causes mild… | 2,770 | $30 | $94.3K |
Showing 1–10 of 84
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 84 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
84 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 87150 | 1 | 10 | 11,000 | $30 | $672.7K |
| P9604 | 2 | 10 | 1,670 | $10 | $290.3K |
| G0471 | 2 | 10 | 23,060 | $10 | $234.1K |
| 87801 | 2 | 20 | 640 | $70 | $148.4K |
| P9603 | 2 | 10 | 34,490 | $1 | $125.9K |
| 87551 | 1 | 10 | 1,910 | $50 | $90.1K |
| 87481 | 4 | 40 | 360 | $30 | $70.3K |
| 83970 | 9 | 20 | 170 | $40 | $47.2K |
| 87186 | 7 | 10 | 2,880 | $10 | $43.5K |
| 83880 | 8 | 30 | 50 | $40 | $37.3K |
Showing 1–10 of 84
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
62 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 3,830 | $70 | $283.4K |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 2,660 | $50 | $119.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 920 | $90 | $84.4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 2,560 | $20 | $58.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 1,140 | $30 | $38.7K |
| 87635 | Using an amplified nucleic acid probe technique, the lab analyst performs the necessary steps to identify the nucleic acids from the severe acute respiratory syndrome coronavirus 2 (SARS–COV–2) virus… | 700 | $50 | $32.2K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 1,320 | $10 | $17.2K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 390 | $30 | $10.9K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 1,430 | $10 | $7.1K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 2,230 | $1 | $6.7K |
Showing 1–10 of 62
How this provider's Medicaid billing volume and revenue compare to other Oklahoma providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Oklahoma median
62 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 2 | 20 | 60 | $60 | $404.2K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 10 | 50 | 330 | $80 | $238.7K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 23 | 40 | 440 | $30 | $230.3K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 45 | 100 | 630 | $50 | $197.2K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 22 | 50 | 170 | $30 | $163.4K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 23 | 50 | 200 | $30 | $163.3K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 8 | 30 | 410 | $130 | $127.9K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 12 | 20 | 300 | $30 | $116.3K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 16 | 80 | 280 | $20 | $72.5K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 63 | 110 | 160 | $80 | $69.9K |
Showing 1–10 of 62
Other providers in the same ZIP code as Wellness Health Group, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.